Expanding the therapeutic index of ADCs

Synaffix’s site-specific–conjugation and payload-enhancement technologies are improving the safety and efficacy of antibody-drug conjugates (ADCs) without the need for antibody engineering. To download the full article, please sign in.

Like Comment
Page of
Go to the profile of Synaffix


Synaffix enables ADCs for oncology that are both safer and more effective as well as easier to manufacture.

No comments yet.